BlackRock, Inc. 13D and 13G filings for Lineage Cell Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-24 08:48 am Purchase |
2025-03-31 | 13G | Lineage Cell Therapeutics, Inc. LCTX |
BlackRock Inc. BLK |
11,453,305 5.000% |
1,358,628 (+13.46%) |
Filing |
| 2025-02-05 5:28 pm Purchase |
2024-12-31 | 13G | Lineage Cell Therapeutics, Inc. LCTX |
BlackRock Inc. BLK |
10,094,677 4.600% |
174,877 (+1.76%) |
Filing |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Lineage Cell Therapeutics, Inc. LCTX |
BlackRock Inc. BLK |
9,919,800 5.300% |
0 (Unchanged) |
Filing |
| 2024-10-22 3:24 pm Purchase |
2024-09-30 | 13G | Lineage Cell Therapeutics, Inc. LCTX |
BlackRock Inc. BLK |
9,919,800 5.300% |
6,164,043 (+164.12%) |
Filing |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Lineage Cell Therapeutics, Inc. LCTX |
BlackRock Inc. BLK |
3,755,757 2.200% |
-6,252,753 (-62.47%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Lineage Cell Therapeutics, Inc. LCTX |
BlackRock Inc. BLK |
10,008,510 5.900% |
10,008,510 (New Position) |
Filing |